Treatment-Resistant Melasma Response to Oral Tranexamic Acid
Journal Title: Journal of Dermatology Research - Year 2024, Vol 5, Issue 3
Abstract
Melasma, a common acquired hyperpigmentation disorder primarily affecting facial skin, poses significant therapeutic challenges due to the limited efficacy and potential side effects of available treatments. Tranexamic Acid (TXA), traditionally used for its hemostatic properties by inhibiting plasminogen activation, has emerged as a promising addition to protocols for treatment-resistant melasma. This study aims to evaluate the efficacy and safety of TXA in combination with Hydroquinone (HQ) and Kojic Acid (KA) in patients with treatment-resistant melasma. We present here a case series of fourteen patients with recurrent melasma refractory to common treatments who achieved successful outcomes with the addition of TXA to their treatment regimen. These patients received 650 mg of TXA in combination with 16% HQ and 6% KA. All patients exhibited a symmetrical reduction in their hyperpigmented patches following treatment and no significant adverse effects were reported. These cases contribute valuable input to the growing body of evidence on the use of TXA for melasma and the combination of treatments and dosing, suggesting its potential as a therapeutic option for this condition. Further research is warranted to explore the mechanisms by which TXA exerts its beneficial effects in melasma and to determine the optimal treatment protocols for achieving effective clinical outcomes.
Authors and Affiliations
Laura Duzett, Bradley Boman, Alison Tam,
Keywords
Related Articles
- EP ID EP747051
- DOI https://doi.org/10.46889/JDR.2024.5304
- Views 27
- Downloads 0
Severe Sunburn as the Overwhelming Risk Factor for 3 Common Skin Cancers: New Prevention Strategy
Re-analysis of published data from two large prospective cohort studies by Wu et al provides hitherto most unequivocal evidence showing Severe Sunburn (SS) as an overwhelming risk factor (> 90%) for all incidences of m...
Perspectives on the FDA’s Sunscreen Policy: New Aging Theory, Sunlight Benefits, Enhanced Immunity, COVID-19 Mortality, Modelling Analyses, Melanoma Risks and Etiology
Currently, the U.S. Food and Drug Administration’s policy on sunscreens assumes that exposure to sunlight, mainly ultraviolet (UV) rays, damages the skin, the damage is cumulative and any sun exposure should be avoided...
After Math of COVID Through Eyes of Tricoscopy
Background: Across the globe from December 2019 until today (COVID -19) has rapidly spread causing pandemic. We have obsevered acute hair loss (TE) in intiating 3-4 months of post COVID infection. Telogen effluvium is a...
Androgenetic Alopecia: A Study on The Efficacy of a Combined Protocol of Blue Light Photobiomodulation and Subcutaneous Infiltrations of Biomimetic Peptides
Androgenetic Alopecia (AGA) is a common condition affecting men and women, characterized by progressive hair follicle miniaturization and consequent hair loss. Blue light Photobiomodulation (PBM) by LED (Light emitting d...
Erythema Nodosum Associated with Terbinafine Therapy- A Case Report
Terbinafine is a commonly used anti-fungal agent in dermatological practice but not one clearly associated with erythema nodosum. There is only one published report in 2014 that described a delayed onset of erythema nodo...